President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government’s Medicare program.

The Centers for Medicare and Medicaid Services said late Friday that it would not cover the medications under Medicare’s Part D prescription drug coverage. Medicare covers health care expenses mainly for people age 65 and older.

Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won reelection that would have extended coverage of drugs like Zepbound and Wegovy. The rule was not expected to be finalized until Trump took office.

CMS did not offer an explanation Friday for its decision.

The injectable treatments have exploded in popularity due to the potentially life-changing weight loss that some patients experience. But many insurers, employers and other bill payers have been reluctant to cover the drugs, which can be used by a wide swath of the population and can cost hundreds of dollars a month.

— The Associated Press